Synopsis
0
VMF
DRUG PRODUCT COMPOSITIONS0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
API SUPPLIERS
Cayman Pharma is Europe's most reliable and versatile source for Prostaglandin APIs//FDA approved.
Click Us!
KDMF
CA, ASMF
Chirogate is a professional Prostaglandin manufacturer.
CEP/COS
JDMF
KDMF
Century has been an API manufacturer for over 40 years & is the partner of choice for multipurpose custom manufacturing projects.
EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.
CEP/COS
JDMF
KDMF
ASMF
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
CEP/COS
JDMF
Gentec Pharmaceutical Group is focused on manufacturing & developing APIs/HPAPIs, Advanced Intermediates & Fine Chemicals.
CEP/COS
ASMF
HRV Global Life Sciences - Market Expansion Leader in Pharmaceuticals.
Tenatra connects Indian manufacturers with global buyers through active partners in Germany, Switzerland, Belgium, Spain & Turkey.
Capital Farma, a leading European pharmaceutical company focusing on the development & distribution of niche APIs & Pharma Services.
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]CEP/COS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API Imports and Exports
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]INTERMEDIATE SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Canada
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Australia
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DRUG PRODUCT COMPOSITIONS
DOSAGE - SOLUTION/DROPS;OPHTHALMIC - 0.005%
USFDA APPLICATION NUMBER - 20597
DOSAGE - EMULSION;OPHTHALMIC - 0.005%
USFDA APPLICATION NUMBER - 206185
Related Excipient Companies
Parenteral
Solubilizers
Digital Content
NEWS #PharmaBuzz
Global Sales Information
US Medicaid Prescriptions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
11
PharmaCompass offers a list of Latanoprost API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Latanoprost manufacturer or Latanoprost supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Latanoprost manufacturer or Latanoprost supplier.
PharmaCompass also assists you with knowing the Latanoprost API Price utilized in the formulation of products. Latanoprost API Price is not always fixed or binding as the Latanoprost Price is obtained through a variety of data sources. The Latanoprost Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A GAAP Ofteno manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of GAAP Ofteno, including repackagers and relabelers. The FDA regulates GAAP Ofteno manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. GAAP Ofteno API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of GAAP Ofteno manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A GAAP Ofteno supplier is an individual or a company that provides GAAP Ofteno active pharmaceutical ingredient (API) or GAAP Ofteno finished formulations upon request. The GAAP Ofteno suppliers may include GAAP Ofteno API manufacturers, exporters, distributors and traders.
click here to find a list of GAAP Ofteno suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A GAAP Ofteno DMF (Drug Master File) is a document detailing the whole manufacturing process of GAAP Ofteno active pharmaceutical ingredient (API) in detail. Different forms of GAAP Ofteno DMFs exist exist since differing nations have different regulations, such as GAAP Ofteno USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A GAAP Ofteno DMF submitted to regulatory agencies in the US is known as a USDMF. GAAP Ofteno USDMF includes data on GAAP Ofteno's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The GAAP Ofteno USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of GAAP Ofteno suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The GAAP Ofteno Drug Master File in Japan (GAAP Ofteno JDMF) empowers GAAP Ofteno API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the GAAP Ofteno JDMF during the approval evaluation for pharmaceutical products. At the time of GAAP Ofteno JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of GAAP Ofteno suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a GAAP Ofteno Drug Master File in Korea (GAAP Ofteno KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of GAAP Ofteno. The MFDS reviews the GAAP Ofteno KDMF as part of the drug registration process and uses the information provided in the GAAP Ofteno KDMF to evaluate the safety and efficacy of the drug.
After submitting a GAAP Ofteno KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their GAAP Ofteno API can apply through the Korea Drug Master File (KDMF).
click here to find a list of GAAP Ofteno suppliers with KDMF on PharmaCompass.
A GAAP Ofteno CEP of the European Pharmacopoeia monograph is often referred to as a GAAP Ofteno Certificate of Suitability (COS). The purpose of a GAAP Ofteno CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of GAAP Ofteno EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of GAAP Ofteno to their clients by showing that a GAAP Ofteno CEP has been issued for it. The manufacturer submits a GAAP Ofteno CEP (COS) as part of the market authorization procedure, and it takes on the role of a GAAP Ofteno CEP holder for the record. Additionally, the data presented in the GAAP Ofteno CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the GAAP Ofteno DMF.
A GAAP Ofteno CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. GAAP Ofteno CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of GAAP Ofteno suppliers with CEP (COS) on PharmaCompass.
A GAAP Ofteno written confirmation (GAAP Ofteno WC) is an official document issued by a regulatory agency to a GAAP Ofteno manufacturer, verifying that the manufacturing facility of a GAAP Ofteno active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting GAAP Ofteno APIs or GAAP Ofteno finished pharmaceutical products to another nation, regulatory agencies frequently require a GAAP Ofteno WC (written confirmation) as part of the regulatory process.
click here to find a list of GAAP Ofteno suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing GAAP Ofteno as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for GAAP Ofteno API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture GAAP Ofteno as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain GAAP Ofteno and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a GAAP Ofteno NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of GAAP Ofteno suppliers with NDC on PharmaCompass.
GAAP Ofteno Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of GAAP Ofteno GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right GAAP Ofteno GMP manufacturer or GAAP Ofteno GMP API supplier for your needs.
A GAAP Ofteno CoA (Certificate of Analysis) is a formal document that attests to GAAP Ofteno's compliance with GAAP Ofteno specifications and serves as a tool for batch-level quality control.
GAAP Ofteno CoA mostly includes findings from lab analyses of a specific batch. For each GAAP Ofteno CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
GAAP Ofteno may be tested according to a variety of international standards, such as European Pharmacopoeia (GAAP Ofteno EP), GAAP Ofteno JP (Japanese Pharmacopeia) and the US Pharmacopoeia (GAAP Ofteno USP).
